Compare Procter & Gamble Co (PG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs TG Therapeutics Inc — how do they compare? Procter & Gamble Co trades at $151.23 (market cap $349.77B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Procter & Gamble Co is far larger — about 42.9× TG Therapeutics Inc's market cap, and Procter & Gamble Co pays a 2.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and TG Therapeutics Inc for 16 Days on average.
| PG | TGTX | |
|---|---|---|
Market Cap | $349.77B | $8.16B |
Volume | 10,055,825 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $59.06 |
52-Week Low | $138.10 | $26.94 |
Typical Hold Time | 131 Days | 16 Days |
Enterprise Value | $375.61B | $8.37B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $151.23, up 2.31% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and consistent earnings beats. Recent partnership with the WNBA and supply chain enhancements support growth. Technical indicators show bullish moving averages while RSI remains neutral.
PG offers stable dividend income with 69-year growth history and trades near consensus target of $160.13. Premium valuation metrics present near-term risk if growth moderates. Strong cash flow generation and institutional support provide downside protection amid market volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
